CurrentBlue Cross Blue Shield - OklahomaPolicy CPCPLAB050

Urine Culture Testing for Bacteria

Defines reimbursement and laboratory management criteria for urine culture testing for bacteria for Blue Cross Blue Shield - Oklahoma; affects providers submitting urine culture tests for members covered under BCBSOK plans.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyUrine Culture Testing for Bacteria

Policy CodePolicy CPCPLAB050

Change TypeNo material change

Effective DateNov 1, 2023

Next Review DateN/A

Key ActionDocument clinical indication and review plan-specific coverage requirements before submitting urine culture test claims.

SourceLink

11/1/2023Plan effective date

7Procedure codes listed

7/17/2023Last literature review

1Policy version

Coverage Criteria for Urine Culture Testing

inv-01: Reimbursable indications for urine culture testing

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Reimbursable scenarios: 1. Pregnant individuals; 2. Asymptomatic individuals undergoing urological interventions which breach the mucosa (pre-procedure); 3. Individuals exhibiting at least one sign or symptom of possible UTI or bacteriuria (see NOTE 1); 4. To assess pyelonephritis.any of the listed conditions

See NOTE 1 for signs/symptoms

inv-02: Not reimbursable

The following are not reimbursable:

Not reimbursable scenarios: 1. All other instances of asymptomatic urinary tract infection or asymptomatic bacteriuria not described in reimbursable scenarios; 2. Follow-up urine culture testing for an uncomplicated UTI when the individual shows evidence of clinical resolution; 3. As part of initial screening for asymptomatic prostatitis; 4. As part of assessment or prognosis of prostate biopsy.n/a

These are explicit non-reimbursable conditions.

Urine culture testing for asymptomatic bacteriuria is generally not reimbursable. Exceptions to this restriction are limited and specific: testing may be covered for pregnant individuals and for asymptomatic individuals undergoing urologic procedures that breach the mucosa (pre-procedural assessment). These exceptions apply when culture with organism identification and antibiotic susceptibilities is performed to guide clinical management in those contexts.

Follow-up urine culture testing after treatment of an uncomplicated urinary tract infection is not reimbursable when the individual shows evidence of clinical resolution. Routine post-treatment cultures in clinically resolved, uncomplicated cases are considered not medically necessary and may be denied.

Specific Covered Indications

inv-15: Pregnancy

Urine culture testing with isolate identification and antibiotic susceptibilities may be reimbursable in pregnant individuals.

Pregnancy: Testing is reimbursable for pregnant individuals when used to evaluate a urinary tract infection; include isolate identification and susceptibilities when applicable.

inv-16: Pre-procedure for urological interventions that breach the mucosa

Asymptomatic individuals may have urine culture testing reimbursed prior to urological procedures that breach the mucosa.

Pre-procedure (mucosal-breaching urologic interventions): Testing is reimbursable for asymptomatic individuals when performed prior to urological interventions that breach the mucosa; include isolate identification and susceptibilities when applicable.

inv-17: Individuals with signs or symptoms of UTI/bacteriuria

Individuals with signs or symptoms of UTI or bacteriuria: at least one sign or symptom listed in NOTE 1 is required for reimbursement.

Symptomatic individuals: At least ONE sign or symptom of possible UTI or bacteriuria (see NOTE 1) must be present to support reimbursement for urine culture testing with isolate identification and susceptibilities when applicable.>= 1 sign or symptom (per NOTE 1)

See NOTE 1 for the list of qualifying signs and symptoms (e.g., fever, urgency, dysuria, frequency, suprapubic tenderness, pyuria, hematuria, flank pain, nausea/vomiting, chills, pelvic pressure, change in urine smell, abnormal urinalysis findings).

inv-18: Assessment of pyelonephritis

Testing to assess suspected pyelonephritis is reimbursable in the context of urgent clinical evaluation.

Assessment of pyelonephritis: Urine culture testing (with isolate identification and antibiotic susceptibilities if applicable) is reimbursable when used to assess pyelonephritis in the setting of urgent clinical evaluation.

Procedure Codes and Coding Notes

Procedure codes (listed)CPT

87077
87086
87088
87140
87147
87149
87181
87186

inv-06: Clinical signs threshold — at least one sign or symptom of UTI/bacteriuria (per NOTE 1)

Clinical thresholdAt least one sign or symptom of possible UTI or bacteriuria (per NOTE 1)

Reference for symptomsSee NOTE 1 for the list of qualifying signs and symptoms (CDC, 2021)

ApplicationRequired for reimbursement when claiming urine culture testing for symptomatic individuals

Limits on Repeat or Follow-up Testing

inv-19: Not reimbursable when individual shows evidence of clinical resolution — follow-up urine culture testing for uncomplicated UTI

Policy statementFollow-up urine culture testing for an uncomplicated urinary tract infection in individuals who show evidence of clinical resolution is not reimbursable.

ContextApplies to routine follow-up cultures after clinical resolution of uncomplicated UTI; considered not medically necessary.

Provider implicationDo not submit claims for follow-up urine cultures for uncomplicated UTI when clinical resolution is documented; such claims may be denied.

Provider Responsibilities and Billing Guidance

Note

Coverage Varies by Product

Coverage may vary by product. Providers should review member plan documents for eligible coverage; not all lab management reimbursement requirements apply to every product.

Documentation Required

Provider Documentation and Coding Responsibilities

Plan and contract precedence; documentation and coding expectations. If a conflict exists between this policy and a member's plan document or a provider contract, the plan document or contract governs. Providers are responsible for submitting accurate documentation and using valid HIPAA-approved codes and industry-standard coding guidelines. Claims are subject to code edit protocols and review; upon request, providers should submit additional documentation.

Submit claims using valid HIPAA-approved code sets (CPT, HCPCS, ICD-10, NDC, UB, DRG as applicable).
Claims are subject to edits and review including plan benefits, provider contract terms, medical and coding policies, and coding software logic.
BCBSOK may use reasonable discretion in interpreting and applying this policy.

Denial Risk

Denial Risk — Asymptomatic Testing

Denial risk — asymptomatic testing. Urine culture testing for asymptomatic UTI or asymptomatic bacteriuria that is not listed among reimbursable exceptions may be denied.

Not reimbursable: asymptomatic urinary tract infection or asymptomatic bacteriuria except when specifically listed as reimbursable (e.g., pregnant individuals, pre-procedural testing for urological interventions that breach the mucosa).
Not reimbursable: initial screening for asymptomatic prostatitis and testing performed as part of assessment or prognosis of prostate biopsy.

Denial Risk

Denial Risk — Routine Follow-up Cultures

Denial risk — routine follow-up cultures. Follow-up urine culture testing for uncomplicated UTI in individuals who show clinical resolution is not reimbursable and may be denied.

Follow-up cultures for uncomplicated UTI after clinical resolution are not reimbursable.

Denial Risk

Denial Risk — Prostate-related Testing

Denial risk — prostate-related screening/assessment. Urine culture testing performed as part of initial screening for asymptomatic prostatitis or for assessment/prognosis of prostate biopsy is not reimbursable.

Not reimbursable: initial screening for asymptomatic prostatitis.
Not reimbursable: testing as part of assessment or prognosis of prostate biopsy.

Ordering and Documentation Requirements

Step Therapy

ORDERING REQUIREMENTS — verify plan coverage and document clinical indication

Providers should review the member’s specific Plan documents to confirm eligible coverage and any ordering requirements; clinical indication must be documented to support reimbursement.

Not all laboratory management reimbursement requirements apply to each product.
Document at least one sign or symptom of UTI/bacteriuria when applicable to support medical necessity.

Definitions and Clinical Signs

inv-14: Signs and symptoms of UTI/bacteriuria

Included symptomsFever

Included symptomsUrgency to urinate; feeling the need to urinate despite an empty bladder; increased frequency of urination

Included symptomsDysuria; suprapubic tenderness; pyuria; hematuria; cloudy urine

Included symptomsLower back/flank pain; nausea; vomiting; chills; night sweats

Included symptomsPelvic pressure; change in urine smell; abnormal urinalysis findings

Background

Urine culture testing is performed to identify bacterial pathogens causing urinary tract infections and to determine organism-specific antibiotic susceptibilities. This information supports diagnosis and targeted therapy in clinical contexts such as lower urinary tract infection (UTI) and pyelonephritis, and is used when signs or symptoms suggest bacteriuria or when pre-procedural assessment in specified situations is required.

Not Covered

The policy does not cover routine urine culture testing for asymptomatic bacteriuria except for the specified exceptions (pregnancy and pre-procedural mucosal-breaching urologic interventions). Additionally, urine culture testing is not reimbursable when performed as part of initial screening for asymptomatic prostatitis or for the assessment or prognosis of prostate biopsy. Follow-up cultures for uncomplicated UTI in individuals who demonstrate clinical resolution are also not covered.

Revision History

2023-11-01policy_effective

Policy became effective for plans on November 1, 2023.

2023-07-17literature_review_and_committee_approvalLatest

Enterprise Clinical Payment and Coding Policy Committee approved the policy following literature review on July 17, 2023.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyUrine Culture Testing for Bacteria

Policy CodePolicy CPCPLAB050

Change TypeNo material change

Effective DateNov 1, 2023

Next Review DateN/A

Key ActionDocument clinical indication and review plan-specific coverage requirements before submitting urine culture test claims.

SourceLink

On This Page